NCT00114101 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 231
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 460
- units
- Participants
- groups
- description
- Beginning between day 100-110, patients receive oral lenalidomide once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.
- id
- BG000
- title
- Lenalidomide Maintenance
- description
- Beginning between day 100-110, patients receive oral placebo once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day. (closed as of 12/17/09)
- id
- BG001
- title
- Placebo Maintenance
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 29
- upper Limit
- 71
- value
- 59
- group Id
- BG001
- lower Limit
- 40
- upper Limit
- 71
- value
- 58
- group Id
- BG002
- lower Limit
- 29
- upper Limit
- 71
- value
- 59
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 110
- group Id
- BG001
- value
- 100
- group Id
- BG002
- value
- 210
- title
- Female
- measurements
- group Id
- BG000
- value
- 121
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 250
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 231
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 460
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 50
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 105
- title
- > 2.5 mg/liter
- categories
- measurements
- group Id
- BG000
- value
- 170
- group Id
- BG001
- value
- 163
- group Id
- BG002
- value
- 333
- title
- <= 2.5 mg/liter
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 22
- title
- Missing data
- param Type
- NUMBER
- title
- Beta 2 microglobulin at registration
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 102
- group Id
- BG001
- value
- 103
- group Id
- BG002
- value
- 205
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 129
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 255
- title
- No
- param Type
- NUMBER
- title
- Prior use of thalidomide during induction
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 160
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 152
- group Id
- BG001
- value
- 148
- group Id
- BG002
- value
- 300
- title
- No
- param Type
- NUMBER
- title
- Prior use of lenalidomide during induction therapy
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 231
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 460
- units
- Participants
- groups
- description
- Beginning between day 100-110, patients receive oral lenalidomide once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.
- id
- BG000
- title
- Lenalidomide Maintenance
- description
- Beginning between day 100-110, patients receive oral placebo once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day. (closed as of 12/17/09)
- id
- BG001
- title
- Placebo Maintenance
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 29
- upper Limit
- 71
- value
- 59
- group Id
- BG001
- lower Limit
- 40
- upper Limit
- 71
- value
- 58
- group Id
- BG002
- lower Limit
- 29
- upper Limit
- 71
- value
- 59
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 110
- group Id
- BG001
- value
- 100
- group Id
- BG002
- value
- 210
- title
- Female
- measurements
- group Id
- BG000
- value
- 121
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 250
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 231
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 460
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 50
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 105
- title
- > 2.5 mg/liter
- categories
- measurements
- group Id
- BG000
- value
- 170
- group Id
- BG001
- value
- 163
- group Id
- BG002
- value
- 333
- title
- <= 2.5 mg/liter
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 22
- title
- Missing data
- param Type
- NUMBER
- title
- Beta 2 microglobulin at registration
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 102
- group Id
- BG001
- value
- 103
- group Id
- BG002
- value
- 205
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 129
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 255
- title
- No
- param Type
- NUMBER
- title
- Prior use of thalidomide during induction
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 160
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 152
- group Id
- BG001
- value
- 148
- group Id
- BG002
- value
- 300
- title
- No
- param Type
- NUMBER
- title
- Prior use of lenalidomide during induction therapy
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle